Kaneka : increases medical catheter production capacity in Vietnam
September 23, 2020 at 05:15 am EDT
Share
―Improves production system and expands intervention business―
Kaneka Corporation
September 23, 2020
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) has decided to increase the medical catheter production capacity of Group subsidiary Kaneka Medical Vietnam Co., Ltd.*1 (Headquarters: Binh Duong, Vietnam; President: Toshiyuki Mori)
In Japan and Vietnam, Kaneka manufactures medical catheters such as endovascular treatment catheters for cardiovascular, peripheral vascular, cerebrovascular disease, gastroenterology intervention for the treatment of gastrointestinal cancer*2 and electrode catheter for irregular pulse test. In order to meet strong and growing global demand, Kaneka will be greatly increasing the production capacity of its Vietnam production facility. It will build a new plant adjacent to its existing plant, roughly tripling its production capacity. Kaneka is investing roughly 1 billion yen in this project, and the new plant is scheduled to go into operation from January 2022.
Populations are aging, especially in developed countries, and the number of patients suffering from cardiac disease, cerebral disorders, and cancer is rising. Surgery using medical catheters is a minimally invasive treatment approach that places less stress on patients, so the global market is expected to grow.
Kaneka will continue to actively launch new products in the intervention business, such as the coil for embolization of brain aneurysms it launched last year or its drug-coated balloon catheters, whose balloons are coated with drugs to prevent cardiovascular restenosis. Furthermore, by reinforcing its expansion into foreign markets such as the markets of the U.S. and Asia, Kaneka aims to achieve 100 billion yen in Medical Solutions Vehicle net sales by 2025.
Kaneka will continue to provide solutions that contribute to minimally invasive treatment using medical catheters and help improve patients' quality of life.
As a company that provides medical solutions, on September 11, Kaneka Pharma Vietnam was renamed Kaneka Medical Vietnam in order to heighten its global presence.
Cancer occurring in the gastrointestinal system, including the esophagus, stomach, small intestine, and large intestine.
< General description of Kaneka Medical Vietnam Co., Ltd.>
Representative: President Toshiyuki Mori
Capital:108.2 billion Vietnamese dong (equivalent to roughly 500 million Japanese yen)
Location: Binh Duong, Vietnam
Foundation: 2005
Description of business: Assembly of medical catheter products
Attachments
Original document
Permalink
Disclaimer
Kaneka Corporation published this content on 23 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2020 09:14:06 UTC
KANEKA CORPORATION is a Japan-based company engaged in four business segments. The Material Solutions Unit segment includes general purpose vinyl chloride resin, caustic soda, polyvinyl chloride special resin, modifier, modified silicone polymer, biodegradable polymer. Quality of Life Solutions Unit segment includes expanded styrene resin and molded products, extruded polystyrene foam boards, bead method expanded polyolefin, solar circuit method, super heat resistant polyimide films, optical materials, super heat conductive graphite sheets, solar cells, storage batteries for housing and others. The Health Care Solutions Unit segment includes medical devices, low molecular weight pharmaceutical raw materials, biopharmaceuticals, etc. The Nutrition Solutions Unit segment includes functional food ingredients, margarine, shortening, baker's yeast, spices, antifreeze ingredients, functional fertilizers and feeds.
KANEKA CORPORATION 
